Get started
PfizerPfizerPfizer

Pfizer

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options Bonds

PFE trade ideas

Pfizer: Oh Buyer Where Art Thou?Pfizer has struggled for years, and some traders may see risk of further downside. The first pattern on today’s chart is the slide to a new 12-year low in October and November. The drugmaker barely retraced half that move at subsequent highs. It also remained mostly below its October low of $26.87. That may suggest old support has become new resistance. Second is PFE’s price action at its 100-day simple moving average (SMA). It fell sharply after breaking that SMA in October and now seems to be stalling at the same line. (See white arrows.) That may reflect a longer-term downtrend. Third, $25.53 was the weekly close in mid-February. It provided support earlier this month, but yesterday the stock returned to the same level. Could that trigger a breakdown? Next, the 50-day SMA had a “death cross” under the 200-day SMA in late November. The 100-day SMA followed in December. The resulting alignment, with faster SMAs under slower ones, is potentially consistent with a downtrend. Finally, PFE is an active underlier in the options market. (TradeStation data shows it ranking 13th in the S&P 500 in the last month, averaging about 110,000 contacts per day.) That could make it easier to position for moves with calls and puts. TradeStation has, for decades, advanced the trading industry, providing access to stocks, options and futures. If you're born to trade, we could be for you. See our Overview for more. Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options or futures); therefore, you should not invest or risk money that you cannot afford to lose. Online trading is not suitable for all investors. View the document titled Characteristics and Risks of Standardized Options at www.TradeStation.com . Before trading any asset class, customers must read the relevant risk disclosure statements on www.TradeStation.com . System access and trade placement and execution may be delayed or fail due to market volatility and volume, quote delays, system and software errors, Internet traffic, outages and other factors. Securities and futures trading is offered to self-directed customers by TradeStation Securities, Inc., a broker-dealer registered with the Securities and Exchange Commission and a futures commission merchant licensed with the Commodity Futures Trading Commission). TradeStation Securities is a member of the Financial Industry Regulatory Authority, the National Futures Association, and a number of exchanges. Options trading is not suitable for all investors. Your TradeStation Securities’ account application to trade options will be considered and approved or disapproved based on all relevant factors, including your trading experience. See www.TradeStation.com . Visit www.TradeStation.com for full details on the costs and fees associated with options. Margin trading involves risks, and it is important that you fully understand those risks before trading on margin. The Margin Disclosure Statement outlines many of those risks, including that you can lose more funds than you deposit in your margin account; your brokerage firm can force the sale of securities in your account; your brokerage firm can sell your securities without contacting you; and you are not entitled to an extension of time on a margin call. Review the Margin Disclosure Statement at www.TradeStation.com . TradeStation Securities, Inc. and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., both operating, and providing products and services, under the TradeStation brand and trademark. When applying for, or purchasing, accounts, subscriptions, products and services, it is important that you know which company you will be dealing with. Visit www.TradeStation.com for further important information explaining what this means.
NYSE:PFE
by TradeStation
12/23/24 - PFE: new BUY mechanical signal.12/23/24 - PFE: new BUY signal chosen by a rules based, mechanical trading system. PFE - BUY Stop Loss @ 24.80 Entry BUY @ 26.71 Target Profit @ 29.54 Analysis: 1. On the Higher timeframe - Prices have stayed above the lower channel line of the ATR (Average True Range) Channel 2. Higher timeframe - Trader Vic's (Victor Sperandeos) 1-2-3/2B Buy pattern...where the lowest current bottom breakout price is greater than the preceding bottom price
NYSE:PFE
by martinmlm
FEAR PRESENTS A BUYING OPPORTUNITYThe deteriorating sentiment over the last 3 years has created a substantial buying opportunity. The negative sentiment can be attributed to 4 main things- decreased EPS/ Net Income since 2022/2023 (end of COVID $$), increased debt levels post-Seagen acquisition and revenue challenges due to upcoming patent expirations. While these concerns are not unwarranted, it is important to note that Pfizer has been through several patent cliffs before while simultaneously growing dividends . The notable upcoming expirations include the pneumonia shot Prevnar in 2026 and the cancer drugs Ibrance and Xtandi, both in 2027. Pfizer has an exceptional history of capital preservation and therefore will continue to take action to address any potential revenue shortfalls including aggressive cost-cutting measures already in progress. From a valuation perspective, PFE's shiller PE is currently 9.51 or 94% as low as it has been in the last 10 years and also 89% better than 462 companies in the drug manufacturing industry. Seeking Alpha gives PFE a grade of F on Growth, but when looking at the individual characteristics not 1 is below a D and only two are D's, and in aggregate looks much better than SA is portraying with a grade of F. Pfizer should not usually be expected to be a grower as it is a mature company. From a technical standpoint it looks like a double bottom is forming at the bottom of a 12 year trend line. The Price/ FCF and EV/EBITDA ratios have decreased back to 2023 and prior levels indicating it is no longer overvalued as it was in 2024. Reverse DCF based on EPS w/out NRI and an 11% discount rate show thaf Pfizer's fair value is $35.89, indicating a 27% margin of safety. The recent volume shows large-scale buying, probably by institutions. Overall I believe the negative sentiment mostly due to the upcoming patent expiration and the realization of loss of revenue from COVID era $ is currently baked into the price and presents a decent buying opportunity.
NYSE:PFELong
by Jrussell86
Pfizer Wave Analysis – 27 March 2025 - Pfizer broke support level 25.20 - Likely to fall to support level 24.70 Pfizer recently broke the pivotal support level 25.20 (lower border of the sideways price range inside which the price has been moving from November). The breakout of the support level 25.20 accelerated the active impulse wave c of the higher impulse wave B from Janaury. Given the clear daily downtrend, Pfizer can be expected to fall to the next support level 24.70 (former strong support from November and the target for the completion of the active wave B).
NYSE:PFEShort
by FxProGlobal
PFE Operation PlanFor this trade on Pfizer (PFE), we will implement a staggered entry strategy with three designated entry points at $26, $25, and $24.5. This approach allows for a cost-averaging method and improved risk management as the market fluctuates. Our profit targets are set at $28, $30.5, and $31, ensuring we capture gains incrementally as the price moves upward. These targets are based on our technical analysis and current market dynamics. Additionally, strict stop-loss protocols will be in place to mitigate downside risks. Disclaimer: This information is provided for educational and informational purposes only and should not be considered financial advice. Trading involves substantial risk, and past performance is not indicative of future results. Always conduct your own research or consult a professional financial advisor before making any investment decisions.
NYSE:PFELong
by Robert_V12
Pfizer ($PFE): Undervalued Pharma Giant with Growth Potential?(1/9) Good afternoon, everyone! 😊 Pfizer ( NYSE:PFE ): Undervalued Pharma Giant with Growth Potential? With PFE at $25.90, is this the time to buy into this pharmaceutical powerhouse? Let’s dive in! 😎 (2/9) – PRICE PERFORMANCE • Current Price: $25.90 as of March 12, 2025 😏 • Recent Moves: Trading within a range of $24 to $28, currently near the middle 😬 • Sector Vibe: Pharma sector remains stable, with new drug approvals driving growth 📈 Short commentary: The stock seems to be consolidating. Is this a good entry point? 🤔 (3/9) – MARKET POSITION • Market Cap: Approximately $147.2 billion (assuming 5.67 billion shares outstanding) 💰 • Operations: Global pharmaceutical company with a diverse product portfolio 🛡️ • Trend: Strong Q4 2024 earnings and reaffirmed 2025 guidance 🚀 Short commentary: Pfizer’s fundamentals are solid, with consistent revenue and earnings projections. 😉 (4/9) – KEY DEVELOPMENTS • Reaffirmed 2025 revenue guidance of $61-64 billion and EPS of $2.80-3.00 📈 • Continued focus on new drug developments and expanding into emerging markets 🌐 • Achieved cost savings goals and ongoing optimization programs for improved margins 💡 Short commentary: The company is managing its costs effectively and looking to future growth. Let’s watch closely. 👀 (5/9) – RISKS IN FOCUS • Legal challenges related to past products ⚙️ • Competition from generic manufacturers and patent expirations 📉 • Economic conditions affecting healthcare spending ⚠️ Short commentary: These risks are known, but Pfizer’s diverse portfolio should help mitigate them. Stay vigilant! 🕵️ (6/9) – SWOT: STRENGTHS • Diverse product portfolio across multiple therapeutic areas 🏆 • Strong R&D capabilities and pipeline of new drugs 🌈 • Global presence and distribution network 🌟 Short commentary: Pfizer’s strengths position it well for long-term growth. Keep up the good work! 👍 (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES • Weaknesses: Dependence on key products, legal issues ⚠️ • Opportunities: New drug approvals, expanding into emerging markets 🌐 Short commentary: Opportunities abound, but weaknesses need to be monitored. Let’s hope they nail it! 📈 (8/9) – PFE at $25.90 – what’s your call? 🗳️ • Bullish: Price could rise to $30+ if it breaks above $28 🚀 • Neutral: Price remains between $24 and $28 😐 • Bearish: Price could drop to $22 if it breaks below $24 📉 Drop your pick below! 💬 (9/9) – FINAL TAKEAWAY Pfizer’s $25.90 stance shows a company with solid fundamentals and a fair valuation at a P/E of approximately 8.93. With a strong pipeline and cost management, it’s an attractive option for value investors. Keep an eye on resistance at $28 for potential upside movement. Snag low, hold long!
NYSE:PFELong
by DCAChampion
PFE 1H Long Swing Conservative Trend TradeConservative Trend Trade + long impulse + SOS level + support level + 1/2 correction + biggest volumed Sp Calculated affordable stop limit 1 to 2 R/R take profit before 1/2 of the Month Expandable to 1/2 of the Year Daily Trend: "+ long impulse + neutral zone + close to 1/2 correction" Monthly CounterTrend "- short balance + unvolumed expanding ICE + volumed 2Sp- + weak test" Yearly Trend "+ long impulse + 1/2 correction + exhaustion volume?" Will add more if corrects to 1/2 of 1H wave.
NYSE:PFELong
by MishaSuvorov
PFE Operation PlanFor this trade on Pfizer (PFE), we will implement a staggered entry strategy with three designated entry points at $27, $26, and $25. This approach allows for a cost-averaging method and improved risk management as the market fluctuates. Our profit targets are set at $29, $30, and $31, ensuring we capture gains incrementally as the price moves upward. These targets are based on our technical analysis and current market dynamics. Additionally, strict stop-loss protocols will be in place to mitigate downside risks. Disclaimer: This information is provided for educational and informational purposes only and should not be considered financial advice. Trading involves substantial risk, and past performance is not indicative of future results. Always conduct your own research or consult a professional financial advisor before making any investment decisions.
NYSE:PFELong
by Robert_V12
PFE - Is There Any Value Here?After achieving the pinnacle of success during the Covid vaccine era, PFE has struggled to recover from falling vaccine sales. I had considered abandoning my core holdings but on further investigation, I liked what they were doing with their cancer drugs and continued to hold. A hefty dividend, albeit not supported much by earnings, continued also to be an attraction. The current washout with the nomination of Robert Kennedy Jr for a cabinet position could have been the last. AI generated pattern finder offers tempting long term gains. Tempting opportunity for those with patience.
NYSE:PFELong
by AssetDesign